| 05/24 | TRANSCRIPT : Basilea Pharmaceutica AG Presents at UBS Global Healthcare Conference, May-24.. | CI |
| 04/27 | Basilea Pharmaceutica Licenses Antifungal Program From US-based Fox Chase | MT |
| 04/27 | Basilea announces licensing of a novel first-in-class antifungal program from Fox Chase.. | AQ |
| 04/27 | Basilea Pharmaceutica AG Announces Licensing of Novel First-In-Class Antifungal Program.. | CI |
| 04/13 | Basilea shareholders approve all proposals of the board of directors at the annual gene.. | GL |
| 04/13 | Basilea Pharmaceutica Ltd. Approves Appointment of Leonard Kruimer as New Member of Boa.. | CI |
| 04/13 | Basilea's Oncology Drug Candidates Show Anti-Cancer Activity in Preclinical Trial | MT |
| 04/13 | Basilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and .. | AQ |
| 04/13 | Basilea Pharmaceutica Ltd. Reports Preclinical Data on Oncology Drug Candidates BAL0891 | CI |
| 03/30 | BASILEA PHARMACEUTICA : Updated March 30, 2022 | PU |
| 03/16 | BASILEA PHARMACEUTICA : Shareholder letter EN | PU |
| 03/08 | Basilea Pharmaceutica's BAL0891 Candidate Shows Anti-Cancer Activity in Preclinical Stu.. | MT |
| 03/08 | Basilea reports preclinical data on anti-cancer activity of novel oncology drug candida.. | DJ |
| 03/08 | Basilea Reports Preclinical Data on Anti-Cancer Activity of Novel Oncology Drug Candida.. | CI |
| 02/21 | BASILEA PHARMACEUTICA : Updated February 21, 2022 | PU |
| 02/15 | TRANSCRIPT : Basilea Pharmaceutica AG, 2021 Earnings Call, Feb 15, 2022 | CI |
| 02/15 | Basilea Pharmaceutica AG Reports Earnings Results for the Full Year Ended December 31, .. | CI |
| 02/15 | BASILEA PHARMACEUTICA : Updated February 15, 2022 | PU |
| 02/15 | Basilea Pharmaceutica Initiates Strategic Review of Oncology Assets | MT |
| 02/15 | Basilea Pharmaceutica's Net Loss Shrinks in FY21 on Anti-Infectives Boost | MT |
| 02/15 | Basilea to become a leading anti-infectives company backed by strong financial results .. | DJ |
| 02/15 | Basilea Pharmaceutica AG Provides Earnings Guidance for the Fiscal Year 2022 | CI |
| 01/24 | Basilea Pharmaceutica's Derazantinib Shows High Disease Control Rate in Bile Duct Cance.. | MT |
| 01/24 | BASILEA PHARMACEUTICA : Updated January 24, 2022 | PU |
| 01/24 | Basilea reports updated interim results for iCCA patients with FGFR2 mutations and ampl.. | DJ |
| 01/24 | Basilea Reports Updated Interim Results for iCCA Patients with FGFR2 Mutations and Ampl.. | CI |
| 01/13 | Basilea-Pfizer's Cresemba Gets China's Approval to Treat Another Fungal Infection | MT |
| 01/13 | Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergi.. | AQ |
| 01/13 | Basilea announces approval of antifungal Cresemba(R) (isavuconazole) for invasive asper.. | DJ |
| 01/11 | Basilea Completes Patient Enrolment For New Antibiotic Study | MT |
| 01/11 | BASILEA PHARMACEUTICA : Updated January 11, 2022 | PU |
| 01/11 | Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigat.. | DJ |
| 01/11 | Basilea Announces Completion of Patient Enrolment in Phase 3 Eradicate Study Investigat.. | CI |
| 01/10 | Basilea Pharmaceutica's Preliminary FY21 Revenue Beats Estimates | MT |
| 01/10 | BASILEA PHARMACEUTICA : Updated January 10, 2022 | PU |
| 01/10 | Basilea exceeds 2021 financial guidance on preliminary revenue and year-end cash-positi.. | DJ |
| 01/10 | Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2021 | CI |
| 01/07 | BASILEA PHARMACEUTICA : Updated January 07, 2022 | PU |
| 01/07 | Basilea To Get $16 Million From Astellas After Strong Antifungal Drug Sales In US | MT |
| 01/07 | Strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million s.. | AQ |
| 01/07 | Strong Cresemba(R) (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million.. | DJ |
| 01/06 | Basilea Expects Late-Stage Data for Anti-Bacterial Drug by Mid-2022 | MT |
| 01/06 | BASILEA PHARMACEUTICA : Updated January 06, 2022 | PU |
| 01/06 | Basilea reports on portfolio progress made in 2021 | DJ |
| 2021 | Basilea Gets $10 Million From Pfizer After Chinese Approval of Antifungal Cresemba | MT |
| 2021 | Basilea receives USD 10 million milestone payment related to approval of antifungal Cre.. | AQ |
| 2021 | Basilea receives USD 10 million milestone payment related to approval of antifungal Cre.. | DJ |
| 2021 | BASILEA PHARMACEUTICA : Updated December 17, 2021 | PU |
| 2021 | Basilea Wins US FDA Nod For Early-Stage Study Of New Cancer Drug | MT |
| 2021 | Basilea announces FDA approval of Investigational New Drug application for novel oncolo.. | DJ |
| 2021 | Basilea Pharmaceutica Ltd. Announces FDA Approval of Investigational New Drug Applicati.. | CI |
| 2021 | Basilea Pharmaceutica Receives $10 Million Milestone Payment from Pfizer | MT |
| 2021 | Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 10 million sales.. | AQ |
| 2021 | Continued strong Cresemba(R) (isavuconazole) sales by Pfizer trigger USD 10 million sal.. | DJ |
| 2021 | Basilea Seeks US FDA's Investigational New Drug Approval For Cancer Therapy | MT |
| 2021 | BASILEA PHARMACEUTICA : Updated November 16, 2021 | PU |
| 2021 | Basilea announces submission of Investigational New Drug application for novel oncology.. | DJ |
| 2021 | Basilea Pharmaceutica Ltd Announces Submission of Investigational New Drug Application .. | CI |
| 2021 | BASILEA PHARMACEUTICA : Therapy Shows Synergistic Anti-Tumor Effects In Gastric Cancer Mod.. | MT |
| 2021 | Basilea presents preclinical data on synergy between derazantinib and paclitaxel in gas.. | DJ |
| 2021 | Basilea Pharmaceutica Ltd Presents Preclinical Data on Synergy Between Derazantinib and.. | CI |
| 2021 | BASILEA PHARMACEUTICA : Asahi Kasei Seek Japanese Nod For Anti-Fungal Drug | MT |
| 2021 | Basilea's partner Asahi Kasei Pharma filed New Drug Application for the marketing autho.. | DJ |
| 2021 | BASILEA PHARMACEUTICA : partner Asahi Kasei Pharma filed New Drug Application for the mark.. | AQ |
| 2021 | BASILEA PHARMACEUTICA : Bile Duct Cancer Drug Shows Improved Efficacy In Updated Mid-Stage.. | MT |
| 2021 | Basilea presents full safety and efficacy data set on derazantinib in patients with FGF.. | DJ |
| 2021 | Basilea Pharmaceutica Ltd. Presents Full Safety and Efficacy Data Set on Derazantinib i.. | CI |
| 2021 | TRANSCRIPT : Basilea Pharmaceutica AG, H1 2021 Earnings Call, Aug 17, 2021 | CI |
| 2021 | Basilea Pharmaceutica Ag Reports Earnings Results for the Half Year Ended June 30, 2021 | CI |
| 2021 | BASILEA PHARMACEUTICA : reports strong financial results for half-year 2021 with significa.. | AQ |
| 2021 | Basilea Pharmaceutica AG Provides Earnings Guidance for the Full Year 2021 | CI |
| 2021 | BASILEA PHARMACEUTICA : Wins Additional $4.3 Million US Funding to Develop Antibiotic | MT |
| 2021 | Basilea awarded additional USD 4.3 million by BARDA to support phase 3 development of c.. | DJ |
| 2021 | BASILEA PHARMACEUTICA : Gets US FDA's Orphan Drug Designation For Brain Cancer Treatment | MT |
| 2021 | Basilea announces U.S. FDA Orphan Drug Designation granted to lisavanbulin for the trea.. | DJ |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
